ARV-393

ARV-393 · Arvinas, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARV-393, covering 2026-02-10 to 2026-02-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. [Phase 1]